At EBMT 2025, Dr. Edouard Forcade presented the results of a multicenter randomized trial comparing cyclosporine (CsA) alone versus CsA plus mycophenolate mofetil (MMF) in patients with intermediate-risk AML in CR1 undergoing reduced-intensity conditioning (Flu-Bu-ATG) allogeneic stem cell transplantation.
The addition of MMF did not significantly reduce acute GVHD grade II-IV, which was the study’s primary objective. However, patients who received CsA+MMF showed a lower 2-year incidence of chronic GVHD, while non-relapse mortality (NRM), relapse incidence (RI), and overall survival (OS) remained comparable between the two groups.
Encouragingly, both arms of the study achieved excellent overall outcomes, with low toxicity and aGVHD incidence, reaffirming the value of RIC alloSCT in this patient population.
The study was conducted by the Acute Leukemia French Intergroup (ALFA) in collaboration with FILO and SFGM-TC.
Thanks to Dr. Forcade and the entire study team for this important contribution to improving GVHD management in AML.
For more details:https://lnkd.in/dDQuwSnD
